Mutational landscape of AML with normal cytogenetics: Biological and clinical implications

Blood Reviews

Volumn 27, Issue 1, 2013, Pages 13-22

  Martelli, Maria Paola ^a   Sportoletti, Paolo ^a   Tiacci, Enrico ^a   Martelli, Massimo F ^a   Falini, Brunangelo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Acute myeloid leukemia; Mutations; Normal karyotype; Whole exome sequencing

Indexed keywords

AZACITIDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; COREPRESSOR PROTEIN; CYTARABINE; DNA METHYLTRANSFERASE 3A; FLT3 LIGAND; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LESTAURTINIB; MIDOSTAURIN; NUCLEOPHOSMIN; PROTEIN BCL 6; QUIZARTINIB; RETINOIC ACID; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CHROMOSOME DUPLICATION; CYTOGENETICS; DRUG MEGADOSE; EPIGENETICS; EXOME; EXON; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HUMAN; KARYOTYPE; NONHUMAN; NUCLEOLAR LOCALIZATION SIGNAL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT;

CCAAT-ENHANCER-BINDING PROTEINS; CYTOGENETIC ANALYSIS; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC HETEROGENEITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; ISOCITRATE DEHYDROGENASE; ISOENZYMES; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84872165619     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.11.001     Document Type: Article

References (148)

1. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
2. Arber D.A., Brunning R.D., Le Beau M.M., Falini B., Vardiman J.W., Porwit A., et al. Acute myeloid leukaemia with recurrent genetic abnormalities. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 110-123. International Agency for Research on Cancer (IARC), Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
3. van der Geer P., Hunter T., Lindberg R.A. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994, 10:251-337.
4. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
5. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003, 3:650-665.
6. Dohner H., Gaidzik V.I. Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program 2011, 36-42.
7. Falini B., Mecucci C., Saglio G., Lo Coco F., Diverio D., Brown P., et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica 2008, 93:439-442.
8. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
9. Slovak M.L., Gundacker H., Bloomfield C.D., Dewald G., Appelbaum F.R., Larson R.A., et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006, 20:1295-1297.
10. Bacher U., Haferlach C., Kern W., Haferlach T., Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood 2008, 111:2527-2537.
11. Mead A.J., Linch D.C., Hills R.K., Wheatley K., Burnett A.K., Gale R.E. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007, 110:1262-1270.
12. Grundler R., Miething C., Thiede C., Peschel C., Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005, 105:4792-4799.
13. Choudhary C., Schwable J., Brandts C., Tickenbrock L., Sargin B., Kindler T., et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 2005, 106:265-273.
14. Falini B., Martelli M.P., Bolli N., Sportoletti P., Liso A., Tiacci E., et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. Blood 2011, 117:1109-1120.
15. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363:2424-2433.
16. Schnittger S., Bacher U., Haferlach C., Alpermann T., Kern W., Haferlach T. Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer 2012, 51:910-924.
17. Gale R.E., Green C., Allen C., Mead A.J., Burnett A.K., Hills R.K., et al. The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111:2776-2784.
18. How J., Sykes J., Gupta V., Yee K.W., Schimmer A.D., Schuh A.C., et al. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. Cancer 2012, [Epub ahead of print]. 10.1002/cncr.27683.
19. Schnittger S., Bacher U., Kern W., Alpermann T., Haferlach C., Haferlach T. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 2011, 25:1297-1304.
20. Whitman S.P., Archer K.J., Feng L., Baldus C., Becknell B., Carlson B.D., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001, 61:7233-7239.
21. Li L., Bailey E., Greenblatt S., Huso D., Small D. Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knock in mice. Blood 2011, 118:4935-4945.
22. Kayser S., Schlenk R.F., Londono M.C., Breitenbuecher F., Wittke K., Du J., et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 2009, 114:2386-2392.
23. Li W., Zhang L., Huang L., Mi Y., Wang J. Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML. Leuk Res 2012, 36:186-191.
24. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
25. DeZern A.E., Sung A., Kim S., Smith B.D., Karp J.E., Gore S.D., et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant 2011, 17:1404-1409.
26. Laboure G., Dulucq S., Labopin M., Tabrizi R., Guerin E., Pigneux A., et al. Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD. Biol Blood Marrow Transplant 2012, 18:1845-1850.
27. Paun O., Lazarus H.M. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission: have the indications changed?. Curr Opin Hematol 2012, 19:95-101.
28. Sengsayadeth S.M., Jagasia M., Engelhardt B.G., Kassim A., Strickland S.A., Goodman S., et al. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant 2012, [Epub ahead of print]. 10.1038/bmt.2012.88.
29. Fathi A., Levis M. FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol 2011, 18:71-76.
30. Zarrinkar P.P., Gunawardane R.N., Cramer M.D., Gardner M.F., Brigham D., Belli B., et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009, 114:2984-2992.
31. Sato T., Yang X., Knapper S., White P., Smith B.D., Galkin S., et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011, 117:3286-3293.
32. Smith C.C., Wang Q., Chin C.S., Salerno S., Damon L.E., Levis M.J., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485:260-263.
33. Pratz K.W., Sato T., Murphy K.M., Stine A., Rajkhowa T., Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010, 115:1425-1432.
34. Falini B., Nicoletti I., Bolli N., Martelli M.P., Liso A., Gorello P., et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007, 92:519-532.
35. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
36. Albiero E., Madeo D., Bolli N., Giaretta I., Bona E.D., Martelli M.F., et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia 2007, 21:1099-1103.
37. Falini B., Bolli N., Shan J., Martelli M.P., Liso A., Pucciarini A., et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006, 107:4514-4523.
38. Falini B., Bolli N., Liso A., Martelli M.P., Mannucci R., Pileri S., et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 2009, 23:1731-1743.
39. Falini B., Martelli M.P., Bolli N., Bonasso R., Ghia E., Pallotta M.T., et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006, 108:1999-2005.
40. Falini B., Lenze D., Hasserjian R., Coupland S., Jaehne D., Soupir C., et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia 2007, 21:1566-1570.
41. Marcucci G., Haferlach T., Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011, 29:475-486.
42. Schneider F., Hoster E., Schneider S., Dufour A., Benthaus T., Kakadia P.M., et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol 2012, 91:9-18.
43. Liso A., Bogliolo A., Freschi V., Martelli M.P., Pileri S.A., Santodirocco M., et al. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. Leukemia 2008, 22:1285-1289.
44. Falini B. Therapy-related acute myeloid leukaemia with mutated NPM1: treatment induced or de novo in origin?. Leukemia 2008, 22:891-892.
45. Alcalay M., Tiacci E., Bergomas R., Bigerna B., Venturini E., Minardi S.P., et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 2005, 106:899-902.
46. Garzon R., Garofalo M., Martelli M.P., Briesewitz R., Wang L., Fernandez-Cymering C., et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008, 105:3945-3950.
47. Haferlach C., Mecucci C., Schnittger S., Kohlmann A., Mancini M., Cuneo A., et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009, 114:3024-3032.
48. Falini B., Macijewski K., Weiss T., Bacher U., Schnittger S., Kern W., et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood 2010, 115:3776-3786.
49. Martelli M.P., Pettirossi V., Thiede C., Bonifacio E., Mezzasoma F., Cecchini D., et al. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood 2010, 116:3907-3922.
50. Jan M., Snyder T.M., Corces-Zimmerman M.R., Vyas P., Weissman I.L., Quake S.R., et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012, 4:149ra18.
51. Grisendi S., Mecucci C., Falini B., Pandolfi P.P. Nucleophosmin and cancer. Nat Rev Cancer 2006, 6:493-505.
52. Federici L., Arcovito A., Scaglione G.L., Scaloni F., Lo Sterzo C., Di Matteo A., et al. Nucleophosmin C-terminal leukemia-associated domain interacts with G-rich quadruplex forming DNA. J Biol Chem 2010, 285:37138-37149.
53. Leong S.M., Tan B.X., Bte Ahmad B., Yan T., Chee L.Y., Ang S.T., et al. Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition. Blood 2010, 116:3286-3296.
54. Bolli N., Nicoletti I., De Marco M.F., Bigerna B., Pucciarini A., Mannucci R., et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res 2007, 67:6230-6237.
55. Vassiliou G.S., Cooper J.L., Rad R., Li J., Rice S., Uren A., et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet 2011, 43:470-475.
56. Falini B., Nicoletti I., Martelli M.F., Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109:874-885.
57. Schneider F., Hoster E., Unterhalt M., Schneider S., Dufour A., Benthaus T., et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood 2009, 113:5250-5253.
58. Schlenk R.F., Dohner K., Krauter J., Frohling S., Corbacioglu A., Bullinger L., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
59. Liso A., Colau D., Benmaamar R., De Groot A., Martin W., Benedetti R., et al. Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules. Leukemia 2008, 22:424-426.
60. Greiner J., Ono Y., Hofmann S., Schmitt A., Mehring E., Gotz M., et al. Mutated regions of nucleophosmin 1 (NPM1) elicit both CD4+ and CD8+ T cell responses in patients with acute myeloid leukemia. Blood 2012, 120:1282-1289.
61. Thiede C., Koch S., Creutzig E., Steudel C., Illmer T., Schaich M., et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006, 107:4011-4020.
62. Mrozek K., Marcucci G., Paschka P., Whitman S.P., Bloomfield C.D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109:431-448.
63. Ferrara F., Izzo T., Criscuolo C., Riccardi C., Muccioli G., Viola A., et al. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan. Biol Blood Marrow Transplant 2010, 16:1018-1024.
64. Röllig C., Bornhauser M., Thiede C., Kramer M., Ho A., Wandt H., et al. Allogenic stem cell transplantation confers a favorable outcome in patients with NPM1 positive acute myeloid leukemia: results from a donor vs. no-donor analysis of 309 patients treated in the SAL AML-2003 trial. Blood 2011, 493. [ASH Annual Meeting Abstracts].
65. Gupta V., Tallman M.S., Weisdorf D.J. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011, 117:2307-2318.
66. Becker H., Marcucci G., Maharry K., Radmacher M.D., Mrozek K., Margeson D., et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28:596-604.
67. Buchner T., Berdel W.E., Haferlach C., Haferlach T., Schnittger S., Muller-Tidow C., et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009, 27:61-69.
68. Dang H., Jiang A., Kamel-Reid S., Brandwein J., Chang H. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype. Hum Pathol Aug 28 2012, [Electronic pub ahead of print].
69. Wetzler M., Kohlschmidt J., Mrozek K., Dombret H., Dohner H., Pilorge S., et al. Prognostic significance of karyotype in octogenarian patients (Pts) with Acute Myeloid Leukemia (AML)-an international study. Blood 2011, 2521. [ASH Annual Meeting Abstracts].
70. Röllig C., Thiede C., Gramatzki M., Aulitzky W., Bodenstein H., Bornhauser M., et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010, 116:971-978.
71. Pogosova-Agadjanyan E., Kopecky K., Petersdorf S., Erba H.P., Stone R., Meshinchi S., et al. Prognostic significance of FLT3 and NPM1 mutations in adults of age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 study: a study by FHCRC and SWOG. Blood 2011, 2520. [ASH Annual Meeting Abstracts].
72. Schlenk R.F., Dohner K., Kneba M., Gotze K., Hartmann F., Del Valle F., et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009, 94:54-60.
73. Burnett A.K., Hills R.K., Green C., Jenkinson S., Koo K., Patel Y., et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 2010, 115:948-956.
74. Schlenk R.F., Dohner K., Krauter J., Gaidzik V., Paschka P., Heuser M., et al. All-Trans retinoic Acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia - results of the AMLSG 07-04 randomized treatment trial. Blood 2011, 80. [ASH Annual Meeting Abstracts].
75. Wermke M., Thiede C., Kiani A., Ehninger G., Bornhauser M., Platzbecker U. Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine. Leukemia 2010, 24:236-237.
76. Sockel K., Wermke M., Radke J., Kiani A., Schaich M., Bornhauser M., et al. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica 2011, 96:1568-1570.
77. Balusu R., Fiskus W., Rao R., Chong D.G., Nalluri S., Mudunuru U., et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 2011, 118:3096-3106.
78. Zhang D.E., Zhang P., Wang N.D., Hetherington C.J., Darlington G.J., Tenen D.G. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 1997, 94:569-574.
79. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001, 27:263-270.
80. Wouters B.J., Lowenberg B., Erpelinck-Verschueren C.A., van Putten W.L., Valk P.J., Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113:3088-3091.
81. Grossmann V., Schnittger S., Schindela S., Klein H.U., Eder C., Dugas M., et al. Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. J Mol Diagn 2011, 13:129-136.
82. Bereshchenko O., Mancini E., Moore S., Bilbao D., Mansson R., Luc S., et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. Cancer Cell 2009, 16:390-400.
83. Greif P.A., Dufour A., Konstandin N.P., Ksienzyk B., Zellmeier E., Tizazu B., et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 2012, 120:395-403.
84. Fasan A., Eder C., Haferlach C., Grossmann V., Kohlmann A., Dicker F., et al. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. Leukemia 2012, [Epub ahead of print]. 10.1038/leu.2012.174.
85. Dufour A., Schneider F., Metzeler K.H., Hoster E., Schneider S., Zellmeier E., et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010, 28:570-577.
86. Pabst T., Eyholzer M., Fos J., Mueller B.U. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009, 100:1343-1346.
87. Green C.L., Koo K.K., Hills R.K., Burnett A.K., Linch D.C., Gale R.E. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010, 28:2739-2747.
88. Taskesen E., Bullinger L., Corbacioglu A., Sanders M.A., Erpelinck C.A., Wouters B.J., et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011, 117:2469-2475.
89. Bacher U., Schnittger S., Macijewski K., Grossmann V., Kohlmann A., Alpermann T., et al. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. Blood 2012, 119:4719-4722.
90. Reitman Z.J., Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010, 102:932-941.
91. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066.
92. Paschka P., Schlenk R.F., Gaidzik V.I., Habdank M., Kronke J., Bullinger L., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28:3636-3643.
93. Nekrutenko A., Hillis D.M., Patton J.C., Bradley R.D., Baker R.J. Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family. Mol Biol Evol 1998, 15:1674-1684.
94. Xu X., Zhao J., Xu Z., Peng B., Huang Q., Arnold E., et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 2004, 279:33946-33957.
95. Schnittger S., Haferlach C., Ulke M., Alpermann T., Kern W., Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010, 116:5486-5496.
96. Abbas S., Lugthart S., Kavelaars F.G., Schelen A., Koenders J., Zeilemaker A., et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia (AML): prevalence and prognostic value. Blood 2010, 116:2122-2126.
97. Patel K.P., Ravandi F., Ma D., Paladugu A., Barkoh B.A., Medeiros L.J., et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 2011, 135:35-45.
98. Damm F., Thol F., Hollink I., Zimmermann M., Reinhardt K., van den Heuvel-Eibrink M.M., et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia 2011, 25:1704-1710.
99. Green C.L., Evans C.M., Hills R.K., Burnett A.K., Linch D.C., Gale R.E. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010, 116:2779-2782.
100. Rakheja D., Konoplev S., Medeiros L.J., Chen W. IDH mutations in acute myeloid leukemia. Hum Pathol 2012, 43:1541-1551.
101. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
102. Patnaik M.M., Hanson C.A., Hodnefield J.M., Lasho T.L., Finke C.M., Knudson R.A., et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 2012, 26:101-105.
103. Tefferi A., Lasho T.L., Abdel-Wahab O., Guglielmelli P., Patel J., Caramazza D., et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010, 24:1302-1309.
104. Zhang Y., Wei H., Tang K., Lin D., Zhang C., Mi Y., et al. Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia. Genet Test Mol Biomarkers 2012, 16:991-995.
105. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
106. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
107. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
108. Marcucci G., Maharry K., Wu Y.Z., Radmacher M.D., Mrozek K., Margeson D., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28:2348-2355.
109. Boissel N., Nibourel O., Renneville A., Gardin C., Reman O., Contentin N., et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2010, 28:3717-3723.
110. Green C.L., Evans C.M., Zhao L., Hills R.K., Burnett A.K., Linch D.C., et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011, 118:409-412.
111. Bestor T.H. The DNA, methyltransferases of mammals. Hum Mol Genet 2000, 9:2395-2402.
112. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
113. Chen Z.X., Riggs A.D. Maintenance and regulation of DNA methylation patterns in mammals. Biochem Cell Biol 2005, 83:438-448.
114. Jurkowska R.Z., Jurkowski T.P., Jeltsch A. Structure and function of mammalian DNA methyltransferases. Chembiochem 2011, 12:206-222.
115. Yamashita Y., Yuan J., Suetake I., Suzuki H., Ishikawa Y., Choi Y.L., et al. Array-based genomic resequencing of human leukemia. Oncogene 2010, 29:3723-3731.
116. Yan X.J., Xu J., Gu Z.H., Pan C.M., Lu G., Shen Y., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011, 43:309-315.
117. Hou H.A., Kuo Y.Y., Liu C.Y., Chou W.C., Lee M.C., Chen C.Y., et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012, 119:559-568.
118. Kihara R., Hoshino H., Kiyoi H., Naoe T. DMT3A and IDH1/2 mutations are stable during the progression of acute myeloid leukemia. Blood 2011, 1466. [ASH Annual Meeting Abstracts].
119. Lin J., Yao D.M., Qian J., Chen Q., Qian W., Li Y., et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One 2011, 6:e26906.
120. Li Y., Zhang D.F., Zhang S.W., Zeng Y., Yao Y.G. Screening for mutation R882 in the DNMT3A gene in Chinese patients with hematological disease. Int J Hematol 2012, 96:229-233.
121. Gaidzik V.I., Schlenk R.F., Paschka P., Stolzle A., Corbacioglu A., Nachbaur D., et al. DNMT3A mutations predict for inferior outcome in NPM1-wildtype and molecular unfavorable cytogenetically-normal acute myeloid leukemia: a study of the German-Austrian AMLSG. Blood 2011, 415. [ASH Annual Meeting Abstracts].
122. Holz-Schietinger C., Matje D.M., Reich N.O. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem 2012, 287:30941-30951.
123. Thol F., Winschel C., Ludeking A., Yun H., Friesen I., Damm F., et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 2011, 96:1870-1873.
124. Walter M.J., Ding L., Shen D., Shao J., Grillot M., McLellan M., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25:1153-1158.
125. Grossmann V., Kohlmann A., Haferlach C., Alpermann T., Wild M., Weissmann S., et al. Landmark analyses of DNMT3A mutations in hematological malignancies. Blood 2011, 407. [ASH Annual Meeting Abstracts].
126. Ribeiro A.F., Pratcorona M., Erpelinck-Verschueren C., Rockova V., Sanders M., Abbas S., et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 2012, 119:5824-5831.
127. Challen G.A., Sun D., Jeong M., Luo M., Jelinek J., Berg J.S., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2011, 44:23-31.
128. Thol F., Damm F., Ludeking A., Winschel C., Wagner K., Morgan M., et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011, 29:2889-2896.
129. Grossmann V., Tiacci E., Holmes A.B., Kohlmann A., Martelli M.P., Kern W., et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood 2011, 118:6153-6163.
130. Shen Y., Zhu Y.M., Fan X., Shi J.Y., Wang Q.R., Yan X.J., et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011, 118:5593-5603.
131. Ko M., Huang Y., Jankowska A.M., Pape U.J., Tahiliani M., Bandukwala H.S., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
132. Gaidzik V.I., Paschka P., Spath D., Habdank M., Kohne C.H., Germing U., et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 2012, 30:1350-1357.
133. Metzeler K.H., Maharry K., Radmacher M.D., Mrozek K., Margeson D., Becker H., et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011, 29:1373-1381.
134. Whitman S.P., Hackanson B., Liyanarachchi S., Liu S., Rush L.J., Maharry K., et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 2008, 112:2013-2016.
135. Paschka P., Marcucci G., Ruppert A.S., Whitman S.P., Mrozek K., Maharry K., et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008, 26:4595-4602.
136. Virappane P., Gale R., Hills R., Kakkas I., Summers K., Stevens J., et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008, 26:5429-5435.
137. Gaidzik V.I., Schlenk R.F., Moschny S., Becker A., Bullinger L., Corbacioglu A., et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009, 113:4505-4511.
138. Schnittger S., Dicker F., Kern W., Wendland N., Sundermann J., Alpermann T., et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 2011, 117:2348-2357.
139. Gaidzik V.I., Bullinger L., Schlenk R.F., Zimmermann A.S., Rock J., Paschka P., et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011, 29:1364-1372.
140. Tang J.L., Hou H.A., Chen C.Y., Liu C.Y., Chou W.C., Tseng M.H., et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009, 114:5352-5361.
141. Tiacci E., Grossmann V., Martelli M.P., Kohlmann A., Haferlach T., Falini B. The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. Haematologica 2012, 97:3-5.
142. Carbuccia N., Trouplin V., Gelsi-Boyer V., Murati A., Rocquain J., Adelaide J., et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010, 24:469-473.
143. Gilliland D.G. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002, 39:6-11.
144. Murati A.A., Brecqueville M.M., Devillier R.R., Mozziconacci M.J., Gelsi-Boyer V.V., Birnbaum D.D. Myeloid malignancies: mutations, models and management. BMC Cancer 2012, 12:304.
145. Fernandez-Mercado M., Yip B.H., Pellagatti A., Davies C., Larrayoz M.J., Kondo T., et al. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS One 2012, 7:e42334.
146. Patel J.P., Gonen M., Figueroa M.E., Fernandez H., Sun Z., Racevskis J., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
147. Grossmann V., Schnittger S., Kohlmann A., Eder C., Roller A., Dicker F., et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012, 120:2963-2972.
148. Roboz G.J. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2011, 43-50.